Application value of Buzhong Yiqi decoction in immunotherapy of NSCLC with negative driver gene
Objective To observe the application value of Buzhong Yiqi decoction in immunotherapy for driver gene negative non-small cell lung cancer(NSCLC).Methods This was a prospective study.A total of 85 patients with driver gene negative NSCLC admitted to Tongxu County Hospital of Traditional Chinese Medicine from March 2020 to May 2022 were included.The enrolled patients were divided into a combined group(43 cases)and a conventional group(42 cases)using the random number table method.In the combined group,there were 30 males and 13 females,aged 45-65(55.25±5.18)years.In the conventional group,there were 32 males and 10 females,aged 47-63(56.14±5.22)years.The conventional group received routine immunotherapy,while the combined group received Buzhong Yiqi decoction on the basis.The short-term efficacy of the two groups was compared after 3 cycles of treatment,and the prognosis of the two groups was compared after 1 year of follow-up.x2 test and t test were used.Results Under different treatment regiments,the objective response rate(ORR)and disease control rate(DCR)of the combined group were 83.72％(36/43)and 93.02％(40/43),which were higher than those of the conventional group[61.90％(26/42)and 69.05％(29/42)],with statistically significant differences(both P＜0.05).Before treatment,there were no statistically significant differences in the immune function between the two groups(all P＞0.05).After treatment,the CD4/CD8 in the combined group was higher than thatin the conventional group,but the levels of interleukin-10(IL-10)and interferon-γ(INF-γ)were lower than those in the conventional group,with statistically significant differences(all P＜0.05).Before treatment,there were no statistically significant differences in the expressions of multidrug-resistance-related proteins between the two groups(both P＞0.05).After treatment,the relative expressions of MRP1 and ERCC1 in the combined group was(12.25±3.41)and(102.45± 20.61),which were both lower than those in the conventional group[(14.39±3.18)and(115.62± 20.33)],with statistically significant differences(both P＜0.05).Under different treatment regimens,the incidence of toxic and side effects in the combined group was 23.26％(10/43),which was lower than that in the conventional group[38.10％(16/42)],with a statistically significant difference(P＜0.05).The progression-free survival(PFS)and overall survival(OS)of the combined group were(8.22±2.41)months and(11.26±2.31)months,which were higher than those of the conventional group[(6.81±2.12)months and(9.44±2.06)months],with statistically significant-differences(both P＜0.05).Conclusion Buzhong Yiqi decoction assisted immunotherapy can improve the short-term efficacy of NSCLC patients with negative driver genes to a certain extent,and has positive significance in enhancing the patients'immunity and chemotherapy tolerance,reducing the risk of toxic and side effects,and prolonging the survival cycle.
万方数据
维普
